Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 348 | 19,145 | 2,978 | 12,772 | 29,111 |
| Gross Profit | 348 | 19,145 | 2,978 | 12,772 | 29,111 |
| Operating Expenses | 55,491 | 54,780 | 71,903 | 56,001 | 54,114 |
| Operating Income | -55,143 | -35,635 | -68,925 | -43,229 | -25,003 |
| Other Income | -16,862 | 18,271 | 29,398 | -48,948 | 8,355 |
| Pre-tax Income | -72,005 | -17,364 | -39,527 | -92,177 | -16,648 |
| Income Tax | N/A | N/A | N/A | N/A | -1 |
| Net Income Continuous | -72,005 | -17,364 | -39,527 | -92,177 | -16,647 |
| Net Income | $-72,005 | $-17,364 | $-39,527 | $-92,177 | $-16,647 |
| EPS Basic Total Ops | -0.61 | -0.15 | -0.34 | -0.91 | -0.18 |
| EPS Basic Continuous Ops | -0.61 | -0.15 | -0.34 | -0.91 | -0.18 |
| EPS Diluted Total Ops | -0.61 | -0.15 | -0.34 | -0.91 | -0.18 |
| EPS Diluted Continuous Ops | -0.61 | -0.15 | -0.34 | -0.91 | -0.18 |
| EPS Diluted Before Non-Recurring Items | -0.41 | -0.15 | -0.49 | -0.95 | -0.18 |
| EBITDA(a) | $-55,079 | $-35,590 | $-68,873 | $-43,178 | $-24,975 |